

5th February 2020

Nuformix plc
 ("Nuformix" or "the Group"),

Director Dealing

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs was notified that on the 24th January 2020, David Tapolczay, Non-Executive Chairman of the Group, sold 650,000 Ordinary Shares ("Ordinary Shares") in the Group at a price of 8.7p per share.

Following the transaction, David Tapolczay's total interest in the Group has decreased to 44,305,000 Ordinary Shares, representing 9.04% of the Group's issued share capital.

1	Details of the person discharging managerial responsibilities.	
a)	Name	David Jozsef Tapolczay
2	Reason for the notification	
a)	Position/status	Non-Executive Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Nuformix plc
b)	LEI	2138003XG3H3I2J3BJ24
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the	Ordinary Shares of 0.1p each

	financial instrument, type of instrument					
	Identification code	GB00BYW79Y38				
b)	Nature of the transaction	Disposal of ordinary Shares				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>8.7p</td> <td>650,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	8.7p	650,000
Price(s)	Volume(s)					
8.7p	650,000					
d)	Aggregated information					
	- Aggregated volume	650,000				
	- Price	8.7p				
e)	Date of the transaction	24/01/2020				
f)	Place of the transaction	Standard List, London Stock Exchange				

Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.

Enquiries:

Nuformix plc

Dr Dan Gooding, Chief Executive Officer

Email: info@nuformix.com

+44 (0)1223 627222

Novum Securities Limited

Jon Belliss / Colin Rowbury

+44 (0)20 7399 9427

About Nuformix plc www.nuformix.com

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2009 and has invested in pharmaceutical cocrystal R&D, establishing world-class capability and know-

how in cocrystal discovery and development, yielding multiple product opportunities.

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.